Oxford Biotherapeutics Collaborate with ImmunoGen on Novel Cancer Drug
OBT continue their progress with this latest collaboration to work on their novel cancer drug development
News
Scancell first patient dosed in Modi-1 Phase 1 trial
Scancell deliver first patient with dose in the Phase 1 Modi-1 trial
‘Meet The Investment Team’ – Smit Mehta
Smit Mehta, investment analyst here at Calculus, answers some questions on the industry, his role and himself
ActiveOps launches new specific workforce management tool CaseworkIQ RegTech
New innovative workforce management tool addresses the specific workforce management needs and regulatory pressure on back-office operations processing case-based work
Calculus VCT Annual General Meeting 2022
31 May 2022 The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held at 1.00pm on 14 of July 2022. The AGM is an important event in the Company’s corporate calendar, providing an opportunity for shareholders to meet the board and put questions to the directors and the investment manager, as …
New study shows Weedingtech’s foamstream technology as effective as conventional more pollutant weed killers
Foamstream performs as well as glyphosate, representing an environmentally friendly and effective alternative method to control weeds.
Invizius Awarded Second Biomedical Catalyst Grant to Research Peritoneal Dialysis Option for its H-Guard® Technology
Invizius has announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard® technology.
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target
Calculus fully exit Genedrive plc for an average ROI of 2.1x
Past performance is not indicative of future performance. Calculus has delivered an average ROI of 2.1x from Genedrive plc (AIM: GDR) through a number of exits in the VCT and EIS Funds. Genedrive, a company we had supported through scale-up, was founded as a contract research business (”CRO”) but refocussed as a Point of Care …
Axol Bioscience raises £3.2 million as part of their latest round
Axol Bioscience, an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that it has raised £3.2 million
MADE appoints Wonderhood Studios as European creative agency
Calculus portfolio company Wonderhood Studios will be working with MADE to help creatively bring to life the brand’s vision, giving it a fresh and bold point of view
Q1 2022 Update
Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Welcome to our first update of 2022. The run up to the tax year end is always a busy time and this year has been no …
Calculus invests in Destiny Pharma
Calculus VCT has invested into Destiny Pharma, a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.
Invizius Awarded Major Biomedical Catalyst Grant
Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic
Arecor Granted Key U.S. Patent Protecting Proprietary Insulin Products
Arecor Granted Key U.S. Patent Protecting Proprietary Insulin Products, AT247 and AT278.
Genedrive announces first NHS deployment of Antibiotic Induced Hearing Loss system
genedrive plc announces that the first six installations of the Antibiotic Induced Hearing Loss system have been deployed to Manchester University NHS Foundation Trust
Job Posting – Chief Operating Officer
Calculus Capital is looking to appoint a Chief Operating Officer. The individual will support the CEO in implementing organisational vision and operational strategy.
Job Posting – Fund Admin Analyst
Calculus Capital is looking for someone to fill the role of Fund Admin Analyst.
Brouhaha Entertainment secures Netflix commission
Netflix has ordered Brouhaha Entertainment’s adaptation of Trent Dalton’s Boy Swallows Universe, more than two years after publisher HarperCollins announced it had sold the screen rights to the author’s debut novel.
Calculus backs MIP Diagnostics with further funding
MIP Diagnostics, a UK nanotechnology business has secured increased investment of its previous round of funding, totalling £7.3M. The joint investment comes from Mercia Asset Management, Calculus Capital, Downing Ventures and BGF, along with an original angel investor.
Raindog Films announce explosive documentary into FIFA’s corruption
Above the Line Productions (a subsidiary of Raindog Films), 101 Studios, Campfire Studios and PZAJ have announced their partnership for a documentary feature on the backdoor dealings and mafia-style tactics plaguing the international governing body, FIFA.
eConsult wins contract with Homerton Emergency Department to help reduce waiting times
eConsult have won a contract to implement their eTriage system in Homerton Emergency Department to enable an electronic check-in service.
Wonderhood Studios releases Devil’s Advocate
Calculus EIS, VCT and Creative Content EIS portfolio company today released the Devil’s Advocate: The Mostly True Story of Giovanni Di Stefano, on Sky and NowTV.
Calculus Capital delivers 1.3x return with sale of digital entertainment company Maze Theory
Maze Theory shares held by Calculus Capital EIS Funds and the Calculus VCT plc have been purchased by a strategic investor, Pluto Digital